<< China << Health << IPO | CAPITAL MARKETS

DualityBio (9606.HK) Officially Lists on Hong Kong Stock Exchange, Embarking on a New Chapter

April 16, 2025
James Tan

DualityBio  has officially commenced trading on the Main Board of the Hong Kong Stock Exchange under the stock code 9606.HK.

The IPO was priced at HK94.60pershare??,raisingapproximately??US94.60 per share, raising approaximaly 211 million (RMB 1.54 billion). Upon full exercise of the over-allotment option (Greenshoe), the total proceeds are expected to reach US$243 million, making it the largest IPO under Hong Kong’s Chapter 18A biotech listing regime in the past four years.

By market close on its debut day, DualityBio’s share price surged 116.7% to HK$205 per share.

15 cornerstone investors participated, including BioNTech, LAV Star, Lake Bleu Prime, Lake Bleu Innovation, TruMed and etc collectively subscribing to US65million(HK65million(HK505 million).

Sponsors & Global Coordinators:

  • Sponsors: Morgan Stanley Asia Limited, Jefferies Hong Kong Limited, and CITIC Securities (Hong Kong) Limited.

  • Joint Global Coordinators, Bookrunners & Lead Managers: Morgan Stanley Asia Limited, Jefferies Hong Kong Limited, CLSA Limited, CICC Hong Kong Securities Limited, and CMBI Capital Markets Limited.